Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Podiatry
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2019
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Podiatry
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2018
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Beth Israel Deaconess Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2016
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Beth Israel Deaconess Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2014
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Esmolol Effects on Heart and Inflammation in Septic Shock
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2014
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2011
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Esmolol for Treatment of Perioperative Tachycardia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2010
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Podiatry
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 30, 2010
Lead Product(s) : Esmolol Hydrochloride
Therapeutic Area : Podiatry
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable